Licensing status

Publication and contact information


Atherosclerosis; inflammation; ischemia/reperfusion injury; sepsis

Sphingosine 1-phosphate receptor 2 (S1PR2; S1P2; EDG5)

Mouse studies suggest inhibitors of S1PR2 could help treat inflammatory vascular disorders. In mice, an S1PR2 antagonist decreased lipopolysaccharide (LPS)-induced increases in inflammation and vascular permeability compared with saline. In the same model, S1pr2-deficient mice showed lower expression of inflammation and coagulation mediators than wild-type mice in response to LPS. Next steps could include evaluating S1PR2 inhibitors in preclinical models for inflammatory vascular disorders such as atherosclerosis and ischemia/reperfusion injury.

SciBX 6(26); doi:10.1038/scibx.2013.668
Published online July 11, 2013

Unpatented; licensing status not applicable

Zhang, G. et al. Blood; published online May 30, 2013;
Contact: Teresa Sanchez, Harvard Medical School, Boston, Mass.